Kyntra Bio, Inc.
$7.34
▼
-1.27%
2026-04-21 07:48:00
www.kyntrabio.com
NMS: KYNB
Explore Kyntra Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$29.62 M
Current Price
$7.34
52W High / Low
$12.6 / $4.85
Stock P/E
0.16
Book Value
$-7.42
Dividend Yield
—
ROCE
-50.18%
ROE
-143.52%
Face Value
—
EPS
$-14.4
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
34
Beta
0.9
Debt / Equity
437.1
Current Ratio
3.39
Quick Ratio
3.26
Forward P/E
-0.7
Price / Sales
4.51
Enterprise Value
$-5.89 M
EV / EBITDA
0.13
EV / Revenue
-0.91
Rating
None
Target Price
$43
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Processa Pharmaceuticals, Inc. | $2.71 | — | $8.25 M | — | -250.81% | -3.73% | $19.63 / $1.76 | $2.17 |
| 2. | Corbus Pharmaceuticals Holdings, Inc. | $10.62 | — | $188.36 M | — | -57.84% | -54.18% | $20.56 / $5.75 | $8.38 |
| 3. | Rapport Therapeutics, Inc. | $37.14 | — | $1.9 B | — | -25.36% | -28.22% | $42.27 / $7.73 | $10.14 |
| 4. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
| 5. | Pharvaris N.V. | $28.97 | — | $1.86 B | — | -54.28% | -65.19% | $29.89 / $13.6 | $5.56 |
| 6. | Revolution Medicines, Inc. | $143.09 | — | $30.24 B | — | -57.28% | -58.07% | $155.7 / $34 | $8.28 |
| 7. | Cartesian Therapeutics, Inc. | $6.94 | — | $183.97 M | — | -30.8% | 195.88% | $15.57 / $5.6 | $-4.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.28 M | 1.08 M | 1.35 M | 2.74 M | -123.26 M | — |
| Operating Profit | -13.52 M | -5.37 M | -11.66 M | -14.79 M | -90.76 M | — |
| Net Profit | -14.22 M | 200.64 M | -7.6 M | 4.64 M | 17.98 M | — |
| EPS in Rs | -3.51 | 49.58 | -1.88 | 1.15 | 4.44 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 6.44 M | 29.62 M | 46.8 M | 140.73 M |
| Operating Profit | -45.34 M | -130.96 M | -310.12 M | -301.02 M |
| Net Profit | 183.45 M | -47.58 M | -284.23 M | -293.65 M |
| EPS in Rs | 45.33 | -11.76 | -70.24 | -72.56 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 119.59 M | 214.53 M | 423.53 M | 610.09 M |
| Total Liabilities | 115.12 M | 398.16 M | 585.73 M | 611.57 M |
| Equity | -30.04 M | -225.6 M | -204.17 M | -21.45 M |
| Current Assets | 99.07 M | 196.51 M | 331.56 M | 492.83 M |
| Current Liabilities | 29.24 M | 133.31 M | 217.67 M | 273.56 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.77 M | -138 M | -315.02 M | -145.93 M |
| Investing CF | 35.42 M | 125.99 M | 153.66 M | 89.12 M |
| Financing CF | -86.03 M | -0.26 M | 122.75 M | 46.78 M |
| Free CF | -4.81 M | -138.26 M | -317.54 M | -184.67 M |
| Capex | -0.04 M | -0.27 M | -2.52 M | -38.74 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -36.71% | -66.74% | — | — |
| Earnings Growth % | 83.26% | 3.21% | — | — |
| Profit Margin % | -160.63% | -607.29% | -208.66% | — |
| Operating Margin % | -442.13% | -662.6% | -213.9% | — |
| Gross Margin % | 47.47% | 91.53% | 85.59% | — |
| EBITDA Margin % | -480.83% | -652.09% | -200.96% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-17 | 1:0.04 |